Tazarotene

Tazarotene

File:Tazarotene.png
Systematic (IUPAC) name
ethyl 6-[2-(4,4-dimethyl-3,4-dihydro-2H-1-benzothiopyran-6-yl)ethynyl]pyridine-3-carboxylate
Clinical data
Pregnancy category	X (U.S.)
Routes of administration	Topical
Legal status
Legal status	Prescription Only
Pharmacokinetic data
Protein binding	>99%
Biological half-life	19 Hours
Identifiers
CAS Number	118292-40-3
ATC code	D05AX05 (WHO)
PubChem	CID 5381
DrugBank	APRD01246
Chemical data
Formula	C21H21NO2S
Molar mass	351.463 g/mol[[]]
(verify)

Tazarotene (marketed as Tazorac, Avage and Zorac) is a prescription topical retinoid sold as a cream or gel. This medication is approved for treatment of psoriasis, acne, and sun damaged skin (photodamage). It is commonly sold in two concentrations: 0.05% and 0.1%.

Common side effects include worsening of acne, dry skin, itchiness, redness and in some cases extreme drying and cracking of skin. For most patients these side effects are uncomfortable but mild and decrease markedly after the first 2–4 weeks of use.

For best results dermatologists recommend applying the cream or gel once daily before bedtime after washing the face with a mild cleanser. Dermatologists recommend using a moisturizer with tazarotene so skin will not be as dry and flaky.

"There is limited evidence that tazarotene and isotretinoin benefit patients with moderate photodamage on the face: both are associated with skin irritation and erythema."

In addition to tretinoin, which has been associated with greater skin improvements with high concentrations, tazarotene and isotretinoin creams are also found to be effective for photodamage, but at the expense of skin irritation. More evidence is needed before any recommendations can be made on oral or topical polysaccharides or hydroxy acids. Evidence from one trial suggests that the effectiveness of 0.05% tretinoin, is equivalent to the effects of 0.05% and 0.1% tazarotene.